Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tracking Federal Agencies’ Enforcement In Supplement Space

This article was originally published in The Tan Sheet

Executive Summary

““The Tan Sheet” provides links to previous articles on many of the enforcements DoJ announced from its year-long sweep.

You may also be interested in...



Supplement Sector Regulatory Milestones: Senators' Enforcement Push, GNC Supply Chain Guidelines

Former FDA OCI Director George Karavetsos says GNC's supply chain guidelines for its vendors is the industry standard, while Sens. Hatch and Heinrich exceeded all standards by recommending DoJ get tougher on firms violating FDA supplement product regulations,

DMAA Supplement Direct Seller Ceases Operations Under Consent Decree

DoJ filed enters consent decree with VivaCeuticals that forces the California firm to cease marketing its RegeneSlim appetite control product, which was found to contain the stimulant DMAA, and because it violated GMP regulations.

Opiate Addiction Treatment Claim Comes With $235,000 Price Tag For Sunrise Nutraceuticals

The proposed order imposes a nearly $1.4m judgment in consumer redress or asset disgorgement, though all but $235,000 is "suspended based on the defendants’ ability to pay," according to FTC. If the firm and its owner "are later found to have misrepresented their financial condition," the entire amount will be due.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS108036

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel